首页> 外文会议>Annual meeting exposition of the Controlled Release Society >Development of Gastric Retained System for Losartan and its Clinical Relevance in HealthyVolunteers with CYP2C9 Polymorphism
【24h】

Development of Gastric Retained System for Losartan and its Clinical Relevance in HealthyVolunteers with CYP2C9 Polymorphism

机译:CYP2C9基因多态性对氯沙坦胃滞留系统的开发及其对健康志愿者的临床意义

获取原文

摘要

The aim of this study was to develop a novel gastricretained losartan dosage for administering losartan 50mgon an once once-daily basis. The gastric floating matrix tabletsprepared from mixtures of HEC 250HHX and sodium odiumbicarbonate increase the gastro gastro-retentive time in vivo andprovide a extend losartan plasma concentration over 24hours. This study indicated that the use of gastric retain retained eddosage form for oral delivery of losartan could be analternative to improve its systemic availability.
机译:这项研究的目的是开发一种新型的胃 保留氯沙坦的剂量,用于服用氯沙坦50mg 每天一次。胃浮基质片 由HEC 250HHX和钠的混合物制备 碳酸氢盐会增加体内胃的胃滞留时间,并且 提供超过24的洛沙坦血浆浓度 小时。这项研究表明使用胃retain留术 口服氯沙坦的剂型可能是 替代方案以提高其系统可用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号